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EDITORIAL
Harnessing the preconditioning phenomenon: does
remote organ ischaemia provide the answer?
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Despite progress in defining the cellular mechanisms of the
ischaemic preconditioning phenomenon, its conversion
into convenient clinical practice has been slow. The
possibility that an innate mechanism of tissue resistance to
ischaemia could be harnessed as a clinical tool is an
attractive and enticing prospect
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I
schaemic injury to vital organs such as the
heart is an extremely common cause of
morbidity and mortality. Limiting tissue
infarction has been a goal for many years, but,
except for rapid reperfusion therapy, there are
currently few therapeutic options. With further
understanding of the pathophysiology of ischae-
mia and revascularisation, it is now known that
cellular injury and the associated clinical man-
ifestations are the result of a ‘‘two pronged
attack’’: the direct effect of ischaemia, and the
subsequent ‘‘reperfusion injury’’. Preserving tis-
sue viability by making the cells more ‘‘resistant’’
to the ischaemic insult is a novel and potentially
important therapeutic approach. It not only has
the potential to limit the extent of damage but
perhaps to extend the therapeutic window for
other interventions such as thrombolysis.
Ischaemic preconditioning is a mechanism that
can protect tissues from both direct ischaemia
and reperfusion injury.
ISCHAEMIC PRECONDITIONING
In a canine model of myocardial infarction,
Murry et al1 first described that pretreatment
with brief periods of ischaemia paradoxically
resulted in a reduction in infarct size. This
process, whereby a tissue undergoes adaptive
and protective changes in response to a small
ischaemic insult, has been termed ‘‘ischaemic
preconditioning’’. This phenomenon appears to
be highly conserved and has been described in a
variety of different species and tissues.2 Both in
vitro3 and in vivo4 5 studies have established that
this important physiological process also occurs
in man.
The process of ischaemic preconditioning
exhibits a biphasic pattern of protection. There
is an early ‘‘classical’’ period of protection
occurring almost immediately after the ischae-
mic stimulus, followed by a ‘‘late precondition-
ing’’ phase, starting 12–42 hours later.6 The exact
mechanisms by which these adaptive changes
are mediated remain unknown. Early precondi-
tioning appears to be conducted through a
pathway activated by a variety of substances
released during ischaemia and reperfusion, such
as adenosine, bradykinin, and opioids. Binding
of these mediators to G protein coupled receptors
stimulates second messenger pathways, and the
translocation of protein kinase C from the cytosol
to the membrane.6 This phosphorylates an as yet
unidentified protein, although candidates such
as the mitochondrial adenosine triphosphate
dependent potassium channel have been pro-
posed.7
In contrast to the early phase, delayed pre-
conditioning is thought to be attributable to
alterations in gene expression, creating a hypoxia
tolerant phenotype. This includes upregulation of
proteins such as growth factors and heat shock
proteins that inhibit apoptosis and maintain
cellular integrity, respectively.6 8
CLINICAL APPLICATIONS OF ISCHAEMIC
PRECONDITIONING
By determining the molecular mechanisms of
preconditioning it is theoretically feasible that
‘‘preconditioning mimicking agents’’ could be
developed to induce these protective and adap-
tive pathways, and hence provide a novel
therapeutic strategy for preserving ischaemic
tissue. A number of agents have been examined
including adenosine analogues (acute myocar-
dial infarction study of adenosine; AMISTAD
trial)9 and stimulators of the mitochondrial
K/ATP channel such as nicorandil.10
Unfortunately the outcomes have been disap-
pointing and inconclusive. This could be due to
the timing of administration (agents given after
reperfusion rather than before or during ischae-
mia) or that a single agent may only act on one
aspect of a complex multifactorial pathway.
Because of this, the translation from experi-
mental observation to therapeutic intervention
has to date proven elusive.
Surgical induction of ischaemic precondition-
ing has been demonstrated. In a study by Yellon
et al,4 myocardial injury was reduced by two
3 minute periods of ischaemic preconditioning
induced by aortic cross clamping before coronary
artery bypass grafting. Ischaemic precondition-
ing has also been shown to provide protection for
the liver during hepatectomy,5 and a reduction in
lung injury following lobectomy.11 These studies
employ an in vivo ischaemic stimulus and
therefore activate the preconditioning pathway
endogenously. This negates the problem asso-
ciated with the singular action of a pharmacolo-
gical mimetic agent. Despite this promising
work, direct preconditioning is not routinely
used in clinical practice and many clinicians
remain to be convinced of its utility. Most studies
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to date involve small numbers of low risk patients where the
additional advantages from preconditioning may be mar-
ginal. In addition, the end points that have been studied are
often an indirect measure of clinical outcome (such as
troponin) and have employed diverse and non-standardised
surrogate markers. Some have also raised concerns about the
practicality and risk of inducing ischaemia, albeit short lived,
in a diseased and vulnerable organ.
REMOTE PRECONDITIONING
In addition to local effects, ischaemia followed by reperfusion
initiates a systemic inflammatory response that is charac-
terised by the production of proinflammatory mediators and
activation of neutrophils. This systemic response is likely to
contribute to the multi-organ dysfunction, such as adult
respiratory distress syndrome and acute renal failure,
associated with the major ischaemic insults of aortic
aneurysm repair, hepatic resection, and cardiopulmonary
bypass. However, systemic effects of briefer periods of
ischaemia can have beneficial protective effects.
Early studies of preconditioning have tended to focus on
the local benefits conferred to one particular organ. The paper
by Kharbanda et al,12 in this issue of Heart, provides further
evidence for a remote widespread and systemic benefit from
ischaemic preconditioning. The study examined an experi-
mental pig model of cardiopulmonary bypass, where remote
ischaemic preconditioning was induced by four 5 minute
cycles of lower limb ischaemia. Both cardiac and pulmonary
injury and acid-base imbalance were reduced by this remote
preconditioning effect. Previous work has also demonstrated
that resistance to ischaemia can develop in areas remote to
the initial ischaemic stimulus. In a study by Gho et al,13 prior
occlusion and reperfusion of rat mesenteric or renal arteries
led to a subsequent reduction in myocardial infarct size, and
lower limb ischaemic preconditioning has been shown to
limit indices of acute lung injury, and myocardial infarct size
in pigs.14 However these studies have used experimental
models of myocardial infarction and the clinical application
of such models is limited since the onset of acute myocardial
infarction can rarely be predicted and a preconditioning
stimulus is not a realistic therapeutic option.
Remote preconditioning presents an exciting clinical
concept with the possibility that regional ischaemia of non-
vital tissue might protect remote organs. This would avoid
the risks associated with inducing direct preconditioning in
the vulnerable target organ. A previous investigation by
Kharbanda et al15 demonstrated that remote preconditioning
can also be induced in man. Ischaemic preconditioning of an
upper limb in healthy human volunteers led to in vivo
attenuation of neutrophil activation and a reduction in
endothethial dysfunction. Normal skeletal muscle is poten-
tially an ideal tissue for the induction of remote precondi-
tioning since it is inherently more resistant to ischaemia than
myocardial or neuronal cells, is capable of regeneration, and
is readily accessible.
LIMITATIONS OF PRECONDITIONING
Despite the valuable contribution that remote precondition-
ing may offer as a convenient clinical tool, many questions
are still unanswered. The exact mechanisms remain to be
elucidated. There has been debate as to whether its effects are
mediated via humoral or neurogenic pathways, or a
combination of both.16 There is also the potential for inter-
tissue variation, with different systems and mechanisms
capable of inducing resistance in some organs but not
others.17
Remote preconditioning faces the same limitations as its
direct counterpart. The timing of the preconditioning
stimulus remains a crucial factor with the major benefits
seen where the onset of ischaemia is known or predictable,
such as cardiopulmonary bypass and organ transplantation.
Moreover, repeated ischaemic stimuli fail to prolong the
period of protection afforded by either classical or late
preconditioning and limits the therapeutic window for this
protective technique. This also has implications for patients
with ongoing or recurrent ischaemia such as those with
stable or unstable angina. The induction of preconditioning
may be difficult to establish or have little incremental benefit
in patients who have ongoing recurrent or critical ischaemia
at presentation. The additive value of additional precondi-
tioning has yet to be established in such clinical settings.
In conclusion, harnessing the potentially powerful and
valuable effects of direct and remote preconditioning is an
exciting and readily achievable therapeutic option in situa-
tions of planned or predictable tissue ischaemia. However,
the clinical utility of routine induction of ischaemic pre-
conditioning has yet to be definitively established in clinical
practice, particularly in patients with known ischaemic
cardiovascular disease or presenting with acute tissue
ischaemia.
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